Aflac (AFL) Set to Announce Earnings on Wednesday

Aflac (NYSE:AFL) is set to issue its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect Aflac to post earnings of $1.67 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Aflac (NYSE:AFL) last posted its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.23. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $4.10 billion. Aflac had a net margin of 28.35% and a return on equity of 16.22%. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 EPS. On average, analysts expect Aflac to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Stock Performance

Shares of AFL stock opened at $112.16 on Wednesday. Aflac has a one year low of $75.07 and a one year high of $115.50. The company has a market cap of $63.73 billion, a P/E ratio of 12.38, a P/E/G ratio of 2.62 and a beta of 0.95. The firm has a 50-day moving average of $109.84 and a 200-day moving average of $96.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.10.

Aflac Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 2nd. Stockholders of record on Wednesday, August 21st were paid a $0.50 dividend. The ex-dividend date was Wednesday, August 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.78%. Aflac’s payout ratio is presently 22.08%.

Analyst Upgrades and Downgrades

AFL has been the topic of several research analyst reports. Evercore ISI boosted their price objective on Aflac from $84.00 to $90.00 and gave the stock an “underperform” rating in a research report on Thursday, September 26th. Morgan Stanley boosted their target price on shares of Aflac from $91.00 to $98.00 and gave the company an “equal weight” rating in a research note on Monday, August 19th. UBS Group raised their price target on shares of Aflac from $84.00 to $109.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. boosted their target price on Aflac from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, October 3rd. Finally, Wells Fargo & Company increased their price target on Aflac from $90.00 to $106.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 10th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, Aflac currently has an average rating of “Hold” and a consensus target price of $97.53.

Insider Activity

In other Aflac news, Director Thomas J. Kenny sold 2,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $98.94, for a total value of $197,880.00. Following the completion of the transaction, the director now directly owns 18,158 shares of the company’s stock, valued at $1,796,552.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is owned by company insiders.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.